Clinical trials: Sirolimus, completed
Advanced Cancer
Docetaxel and Sirolimus in Patients With Advanced Malignancies
The goal of this clinical research study to find the highest tolerated dose of the combination of Taxotere (docetaxel) and Rapamycin (sirolimus) when given to patients with advanced cancer.
- Trial name
- NCT01054313
- Testing
- Docetaxel (Taxotere), Sirolimus (Rapamycin), Prednisone
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Allograft Dysfunction in Renal Transplantation
Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients
Despite the remarkable improvement in short-term patient and graft survival among the recipients of kidney transplants, the progressive renal dysfunction (chronic allograft dysfunction) accompanied by chronic interstitial…
- Trial name
- NCT01046045
- Testing
- everolimus
- Where
- Hong Kong
- Volunteers
- 17 people
- Sponsor
- Chinese University of Hong Kong
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer
SORAVE - Sorafenib and Everolimus in Solid Tumors
Dose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished).
- Trial name
- SORAVE (NCT00933777)
- Testing
- Combination of sorafenib and everolimus
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- University of Cologne
Prostate Cancer
CCI-779 in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to determine the effectiveness of CCI-779 in treating patients who have…
- Trial name
- NCT00012142
- Testing
- temsirolimus
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Desmoid Tumor
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid-type fibromatosis (or desmoid tumor) represents an intermediate grade neoplasm with a striking predilection for locally invasive growth and recurrence following resection. It occurs in children as well as young adults.
- Trial name
- NCT01265030
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- MaineHealth
Non-small Cell Lung Cancer, Locally Advanced Disease
Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer
The phase 1 study evaluats RAD001 in combination with radiotherapy in non-small cell lung cancer. First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy…
- Trial name
- RAD001 (NCT01167530)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Clear Cell Renal Cell Carcinoma
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
This is an open labeled phase I dose escalation study of hydroxychloroquine (HCQ) and RAD001 in patients with advanced renal cell carcinoma followed by a Phase II trial of RAD001 with HCQ.
- Trial name
- NCT01510119
- Testing
- Hydroxychloroquine, RAD001
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Graves Ophthalmopathy
Sirolimus in Graves' Orbitopathy
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast…
- Trial name
- RETROSIRGO (NCT05345119)
- Testing
- Sirolimus, Methylprednisolone
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Renal Transplantation
Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation
To investigate in renal transplant recipients the potential drug intreaction between Sirolimus, Mycophenolt Mofetil and Fluvastatin All patient enrolled in this PKI-Study had no changes in the therapy before or because of the…
- Trial name
- NCT00223028
- Testing
- sirolimus, mycophenolat mofetil, fluvastatin
- Volunteers
- 15 people
- Sponsor
- University Hospital Schleswig-Holstein
Coronary Artery Disease
The Arterial Revascularization Therapies Study Part II.
The main objective is to compare the effectiveness of coronary stent implantation using the sirolimus-eluting Bx VELOCITY™ balloon expandable stent with that of surgery as observed in ARTS I.
- Trial name
- ARTS II (NCT00235170)
- Testing
- drug-eluting stent
- Where
- Netherlands
- Volunteers
- 607 people
- Sponsor
- Cordis US Corp.
Renal Transplant
Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression
Damage and scarring of a transplanted kidney has become the most common cause of loss of the transplanted kidney. This kidney damage is a complex process caused by many factors including injury during obtaining and transplanting…
- Trial name
- CNI-W (NCT00555373)
- Testing
- Sirolimus
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pediatric Nephrology of Alabama
Peripheral Artery Disease
BRight Pharmacokinetic Study
The BRight PK Study is a prospective, single-arm, open-label, non-blinded, non-randomized study, which goal is to assess the pharmacokinetic profile of the BRight drug-coated balloon at different time points after the balloon…
- Trial name
- NCT06065345
- Testing
- BRight DCB
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Biotronik CRC Inc.
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg…
- Trial name
- INTORSECT (NCT00474786)
- Testing
- Sorafenib, temsirolimus (Torisel)
- Where
- 128 sites in United States, Argentina and 18 more
- Volunteers
- 512 people
- Sponsor
- Pfizer
Leiomyosarcoma, Liposarcoma
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00093080
- Testing
- ridaforolimus
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Prostate cancer is a common and important health issue. Although effective treatment is often available for localized disease, metastatic prostate cancer remains incurable.
- Trial name
- NCT00574769
- Testing
- RAD001, Docetaxel, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Autosomal Dominant Polycystic Kidney Disease
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as…
- Trial name
- NCT00414440
- Testing
- Everolimus
- Where
- 24 sites in Austria, France and 1 more
- Volunteers
- 431 people
- Sponsor
- Novartis Pharmaceuticals
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The aim of our study is to investigate whether Rapamune used at a low dose (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with ADPKD.
- Trial name
- NCT00346918
- Testing
- Sirolimus, Standard
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Renal Transplantation
Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
The purpose of this study is to assess if a combination of everolimus, steroids, and mycophenolate mofetil is associated with a better renal function than sirolimus.
- Trial name
- NCT00170820
- Testing
- Everolimus
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.